0000899243-19-006729.txt : 20190307
0000899243-19-006729.hdr.sgml : 20190307
20190307172023
ACCESSION NUMBER: 0000899243-19-006729
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190305
FILED AS OF DATE: 20190307
DATE AS OF CHANGE: 20190307
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brady Todd C
CENTRAL INDEX KEY: 0001579179
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36332
FILM NUMBER: 19666785
MAIL ADDRESS:
STREET 1: C/O EVOKE PHARMA, INC.
STREET 2: 505 LOMAS SANTA FE DRIVE
CITY: SOLANA BEACH
STATE: CA
ZIP: 92075
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc.
CENTRAL INDEX KEY: 0001341235
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 131 HARTWELL AVENUE
STREET 2: SUITE 320
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-761-4904
MAIL ADDRESS:
STREET 1: 131 HARTWELL AVENUE
STREET 2: SUITE 320
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: Aldexa Therapeutics, Inc.
DATE OF NAME CHANGE: 20130102
FORMER COMPANY:
FORMER CONFORMED NAME: Neuron Systems Inc
DATE OF NAME CHANGE: 20051012
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-03-05
0
0001341235
Aldeyra Therapeutics, Inc.
ALDX
0001579179
Brady Todd C
C/O ALDEYRA THERAPEUTICS, INC.
131 HARTWELL AVENUE
LEXINGTON
MA
02421
1
1
0
0
President and CEO
Common Stock
2019-03-05
4
A
0
250000
0.00
A
556054
D
Employee Stock Option (Right to Buy)
8.05
2019-03-05
4
A
0
250000
0.00
A
2029-03-04
Common Stock
250000
250000
D
Bonus Units
8.05
2019-03-05
4
A
0
45329
0.00
A
Common Stock
45329
45329
D
Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2019, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date.
Includes 3,571 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan (ESPP) in 2018.
The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2019.
The bonus units vest in four (4) annual installments from the date of grant and entitle the Reporting Person to receive a cash payment, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the amount by which the then value of the Issuer's common stock exceeds the base value of $8.05.
/s/ Todd C. Brady
2019-03-07